Bank of New York Mellon’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-12,755
| Closed | -$19.1K | – | 4510 |
|
|
2023
Q1 | $19.1K | Hold |
12,755
| – | – | ﹤0.01% | 4314 |
|
|
2022
Q4 | $12.7K | Hold |
12,755
| – | – | ﹤0.01% | 4401 |
|
|
2022
Q3 | $23K | Hold |
12,755
| – | – | ﹤0.01% | 4438 |
|
|
2022
Q2 | $37K | Sell |
12,755
-90,715
| -88% | -$224K | ﹤0.01% | 4417 |
|
|
2022
Q1 | $285K | Sell |
103,470
-7,893
| -7% | -$24.8K | ﹤0.01% | 4039 |
|
|
2021
Q4 | $519K | Buy |
111,363
+4,021
| +4% | +$25.1K | ﹤0.01% | 3794 |
|
|
2021
Q3 | $913K | Sell |
107,342
-8,550
| -7% | -$121K | ﹤0.01% | 3441 |
|
|
2021
Q2 | $1.9M | Sell |
115,892
-9,188
| -7% | -$186K | ﹤0.01% | 3011 |
|
|
2021
Q1 | $2.76M | Sell |
125,080
-285
| -0.2% | -$7.77K | ﹤0.01% | 2742 |
|
|
2020
Q4 | $3.88M | Buy |
125,365
+47,689
| +61% | +$1.21M | ﹤0.01% | 2480 |
|
|
2020
Q3 | $1.58M | Buy |
77,676
+23,086
| +42% | +$405K | ﹤0.01% | 2809 |
|
|
2020
Q2 | $839K | Buy |
54,590
+13,115
| +32% | +$151K | ﹤0.01% | 3208 |
|
|
2020
Q1 | $321K | Hold |
41,475
| – | – | ﹤0.01% | 3573 |
|
|
2019
Q4 | $592K | Buy |
41,475
+12,412
| +43% | +$192K | ﹤0.01% | 3507 |
|
|
2019
Q3 | $437K | Buy |
+29,063
| New | +$453K | ﹤0.01% | 3603 |
|
Bank of New York Mellon's TCRR Position: Q2 2023 in Review
Bank of New York Mellon sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 12,755 shares — an estimated $19.1K sold.
Bank of New York Mellon first reported a position in TCRR in Q3 2019 and held it in 15 quarters. The position peaked at $3.88M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Bank of New York Mellon reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of New York Mellon sold 12,755 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $19.1K.
- Bank of New York Mellon first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Bank of New York Mellon's TCR2 Therapeutics Inc. Common Stock position peaked at $3.88M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.